Led by Entrepreneurs - Backed by Private Investors
MedXCell is a Swiss biotech venture builder led by entrepreneurs and backed by private investors. Our operating model involves co-designing early-stage projects with academic institutions, followed by the creation of self-standing ventures centered around the most commercially-viable ideas.
We then finance and manage the operations of these ventures before integrating co-investors for later-stage development. MedXCell's current portfolio includes CYTEA BIO and BIORESPX, two robust technological platforms that have advanced to the non-clinical proof of concept (POC) stage.
Our focus is on technologies, techniques or a novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders.
Established in 2018, we have offices in Switzerland (Montreux), France (Montpellier) and the US (Cambridge, MA) and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development and funding capabilities.
Sites
Technological platforms
CHF raised
Our Mission
Our mission is to identify scientific breakthroughs and transform them into clinical assets.
Operating Model
Select
Discover
Scale
Develop
Differentiations
Fast & Efficient
In developing multiple projects and ideas at the same time.
Economies of Scale
In the otherwise costly early-stage development period.
Benefit
From creating cross-venture synergies.
Invest
For a longer time and in multiple rounds (often alongside partner investors or non-related VC’s).
- Portfolio Asset N°1
Visit cytea.bio
- Portfolio Asset N°2
BIORESPX
More information coming soon.
Passionate People
Team Behind MedXCell
Team Behind MedXCell
MedXCell has a core expertise in biotechnology, with decades of relevant experience among its employees. There is a particularly strong experience in working at the academic / industry interface and bringing academic technology developments to successful monetization.
In addition, Medxcell’s executives have extensive experience in technology evaluation, IP creation, translational development, pharmaceutical product development, clinical practice and registration.